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Background: Control of RNA polymerase II (RNAPII) release from pausing has been proposed as a checkpoint
mechanism to ensure optimal RNAPII activity, especially in large, highly regulated genes. HIV-1 gene expression is
highly regulated at the level of elongation, which includes transcriptional pausing that is mediated by both viral
and cellular factors. Here, we present evidence for a specific role of the elongation-related factor TCERG1 in
regulating the extent of HIV-1 elongation and viral replication in vivo.
Results: We show that TCERG1 depletion diminishes the basal and viral Tat-activated transcription from the HIV-1
LTR. In support of a role for an elongation mechanism in the transcriptional control of HIV-1, we found that TCERG1
modifies the levels of pre-mRNAs generated at distal regions of HIV-1. Most importantly, TCERG1 directly affects the
elongation rate of RNAPII transcription in vivo. Furthermore, our data demonstrate that TCERG1 regulates HIV-1
transcription by increasing the rate of RNAPII elongation through the phosphorylation of serine 2 within the
carboxyl-terminal domain (CTD) of RNAPII and suggest a mechanism for the involvement of TCERG1 in relieving
pausing. Finally, we show that TCERG1 is required for HIV-1 replication.
Conclusions: Our study reveals that TCERG1 regulates HIV-1 transcriptional elongation by increasing the elongation
rate of RNAPII and phosphorylation of Ser 2 within the CTD. Based on our data, we propose a general mechanism
for TCERG1 acting on genes that are regulated at the level of elongation by increasing the rate of RNAPII transcription
through the phosphorylation of Ser2. In the case of HIV-1, our evidence provides the basis for further investigation of
TCERG1 as a potential therapeutic target for the inhibition of HIV-1 replication
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Gene transcription begins with the recruitment and as-
sembly of an RNA polymerase II (RNAPII) complex on
core promoter sequences, followed by initiation of RNA
synthesis and subsequent elongation. Most of the initial
studies to improve the understanding of transcriptional
regulation were focused on the initiation stage and
the mechanism by which the RNAPII complexes were* Correspondence: csune@ipb.csic.es
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reproduction in any medium, provided the orrecruited and assembled on promoters (reviewed in [1]).
However, transcription elongation is also a major target
for gene regulation. Initial studies of the Hsp70 gene in
Drosophila have shown that RNAPII complexes stall in
the 5′ region of the transcription unit [2]. Paused RNAPII
within the promoter-proximal region has also been
observed at many proto-oncogenes, such as c-myb [3],
c-mos [4], c-myc [5], and c-fos [6], and other mammalian
genes [7-9], suggesting that RNAPII pausing at promoter-
proximal regions is predominantly the rule rather than
the exception. More recently, genome-wide results fromtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for the widespread existence of paused RNAPII at gene
promoter-proximal regions [10-15]. Thus, increasing
evidence suggests that RNAPII often arrests within the
vicinities of the start site of transcription and that
release of paused RNAPII might act as an important
checkpoint to ensure optimal RNAPII activity, especially
in large, highly regulated genes (reviewed in [16]). In
addition to promoter-proximal pausing, two recent
reports using global analysis of nascent RNA in yeast
have shown that RNAPII transiently accumulates at
specific sites before termination and around 3′ splice
sites of genes [17,18]. Although the nature and position
of the observed pausing differ between the studies, a
strong correlation between paused RNAPII and co-
transcriptional splicing was observed. These observations
agree with the model in which transcriptional pausing acts
as a regulatory checkpoint, in this case for a downstream
processing event.
Differences in the phosphorylation status of the tandem
repeats of the consensus heptapeptide YSPTSPS in the
carboxyl-terminal domain (CTD) of the largest subunit of
RNAPII have been associated with the location of RNAPII
on the gene. Hypophosphorylated RNAPII assembles into
pre-initiation complexes at gene promoters, whereas
hyperphosphorylated RNAPII associates with the elong-
ation stage. Cyclin-dependent kinase 7 (CDK7), which
is part of the general transcription factor IIH (TFIIH),
is responsible for the phosphorylation of serines at the
fifth position (Ser5). This modification has been linked
with transcription initiation and is preferentially associated
with the 5′-end of the genes. As RNAPII elongates further
downstream, phosphorylation of serines at the second
position (Ser2) increases, which is viewed as an elongation
mark and is preferentially associated with the 3′-end of
the genes. The transition between Ser5 and Ser2 phos-
phorylation is essential for the release of paused RNAPII
complexes from the proximal promoter and represents an
important mechanism of control for proper elongation.
Extensive phosphorylation of Ser5 has also been found
in the CTD of RNAPII paused around 3′ splice sites of
genes [17]. Phosphorylation of Ser2 of the CTD could
conceivably also be associated with release from this
pausing. Although the correlation between Ser2 phos-
phorylation and elongation is widely accepted, recent
discoveries related to modifications of the CTD and the
enzymes involved show that this model is an oversim-
plified representation of a more complex process regu-
lating elongation control of gene expression (reviewed
in [19-21]).
Human Immunodeficiency virus type 1 (HIV-1), the
etiologic agent of acquired immunodeficiency syndrome
(AIDS), is a complex lentivirus with a highly regulated life
cycle. Upon infection, HIV-1 integrates into the hostgenome DNA where it remains in a silent state, which is
critical in latently infected cells. The chromatin structure,
as well as a specific group of proteins, plays a role in
repressing viral gene expression by causing the RNAPII
complexes to pause in the 5′ region of the transcription
unit. It is now well established that Nuc-1, a nucleosome
located immediately downstream of the HIV-1 transcrip-
tional initiation site, directly represses promoter activity
and is mainly responsible for transcriptional silencing
in latently infected cells. Consequently, the synthesized
transcripts fail to support viral replication [22]. In recent
work, a mechanism involving the microprocessor complex
as well as specific termination factors has been proposed
to regulate pausing and premature termination at the
HIV-1 Long Terminal Repeat (LTR) [23]. HIV-1 tran-
scription is controlled by cis-acting sequences located
at the 5′ LTR and by both viral and cellular trans-acting
factors [24]. Among other sequences, the LTR contains a
canonical TATA-box sequence followed by two NF-κΒ
and three Sp1 sites that constitute the core promoter
and modulate basal and activated viral transcription
[25]. Activation of this promoter requires expression of
the viral regulatory protein Tat, which binds to a 59-nt
stem-bulge-loop structured RNA element named TAR
(for trans-activation-responsive region) located at the
5′-end of all HIV-1 nascent transcripts [26]. The tran-
scriptional trans-activation of the HIV-1 promoter by Tat
requires specific cellular cofactors. The complex P-TEFb
is a Tat cofactor that is essential for the transcriptional
function of Tat [27-29] and is recruited to the TAR
element through the interaction of Tat with cyclin T1
(a component of P-TEFb). The CDK9 component of P-
TEFb phosphorylates Ser2 within the CTD of RNAPII
as well as several positive and negative elongation fac-
tors. These events lead to release of the arrested RNA
complexes in the 5′ region of the transcription unit,
resulting in a potent stimulation of the overall rate of
transcriptional elongation and productive HIV-1 repli-
cation. In addition to the essential role of the Tat/TAR
axis in the control of HIV-1 gene expression and latency,
the HIV TATA-box and immediately flanking sequences
have been shown to be specifically required for the pro-
duction of specific pre-initiation complexes that are
targets of trans-activation by Tat [30-35]. In this con-
text, Tat plays a highly specific role in the recruitment
of transcription factors and co-activators through its
multifaceted interactions with different cellular compo-
nents [36-44]. Therefore, HIV-1 transcription is a critical
step in the viral life cycle, and the intricate regulation of
this transcription provides the basis for understanding
viral transcriptional latency [45-48].
In addition to P-TEFb, other factors have been impli-
cated in the mechanism of Tat-mediated transcriptional
activation. Among these, TCERG1 (HUGO approved gene
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designated CA150, for co-activator of 150 kDa) is a nu-
clear protein that was first detected in a fraction from a
wild-type Tat affinity column that contained an activity
required for transcription activation by Tat in an
in vitro transcription system [49]. We have previously
shown that immunodepletion of TCERG1 from nuclear
extracts decreases Tat activation of RNAPII elongation
efficiency in vitro, suggesting that TCERG1 might play
a positive role in this process [49]. We have also shown
that transient overexpression of TCERG1 protein in
HEK293T cells reduces the activity of HIV-1 basal and
Tat-activated transcription of the HIV-1 LTR by decreasing
the level of elongation-competent transcription complexes.
We hypothesized that overexpression of TCERG1 might
alter the composition of the Tat-responsive transcription
complexes, e.g. by sequestering a limiting Tat-cofactor
[50]. Based on these and other data, such as the inter-
action of TCERG1 with several components of the
elongation machinery [51] and with the phosphorylated
CTD of RNAPII [52], TCERG1 appears to function in
the elongation stage of transcription. The aforemen-
tioned data strongly suggested that TCERG1 is a cofac-
tor for HIV-1 transcriptional elongation and thus might
be a relevant protein in the HIV-1 life cycle. However,
this hypothesis has not previously been formally tested
in vivo.
Very recently, we have demonstrated that TCERG1
regulates the expression of the apoptosis gene Bcl-x by
modulating the rate of RNAPII transcription. In this pre-
vious work, we proposed that TCERG1 acts on RNAPII
to relieve pausing, thus acting as a checkpoint factor to
ensure optimal RNAPII activity during elongation [53].
These results posit the question of whether the effect of
TCERG1 on Bcl-x elongation is a more general mechan-
ism that operates in other genes that harbor pause sites,
e.g., in HIV-1. In this manuscript, we evaluate the role
of endogenous TCERG1 in HIV-1 transcription and viral
replication in vivo. We found that TCERG1 depletion
diminishes the basal and Tat-activated transcription from
the HIV-1 LTR by impairing elongation of the HIV-1
transcripts. Most importantly, TCERG1 affects the rate
of RNAPII transcription of HIV-1. We also observed that
the TCERG1-mediated transcriptional effect is associated
with changes in the pattern of Ser2 phosphorylation in
the RNAPII CTD. In addition, we show that TCERG1
is required for HIV-1 replication, as depletion of TCERG1
decreased viral replication in Jurkat cells and peripheral
blood lymphocytes (PBLs). Based on our data, we propose
a general mechanism for TCERG1 acting on genes
that are regulated at the level of elongation by increas-
ing the rate of RNAPII transcription through the
phosphorylation of Ser2. In the case of HIV-1, our evi-
dence provides the basis for further investigation ofTCERG1 as a potential therapeutic target for the in-
hibition of HIV-1 replication.
Results
TCERG1 depletion decreases basal and Tat-activated
transcription from the HIV-1 LTR
As a first approach to test the role of TCERG1 in HIV-1
transcription, we examined PBLs co-transfected with a
luciferase expression vector under the control of the
HIV-1 LTR promoter along with the following vectors to
induce TCERG1 mRNA interference: pGeneClip-shTCER
G1-C1 or pGeneClip-shTCERG1-3 and pGeneClip-sh
TCERG1-4, and the latter pair together with pGeneClip-
shTCERG1-1. TCERG1 knockdown was assessed by
quantitative RT-PCR assay (qRT-PCR) (Figure 1A). PBLs
were transfected in a resting state and then maintained
with IL-2 for 48 hours. Upon quantification of the lu-
ciferase activity, we observed that TCERG1 knockdown
significantly reduced the basal transcription of the LTR
(Figure 1A, left panel). Similar results were observed when
the experiment was performed in the presence of Tat.
Tat-mediated transcriptional activation of the luciferase
reporter gene was reduced upon TCERG1 depletion in
PBLs (Figure 1A, right panel). Tat expression in the nucleus
of the transfected cells was assessed by immunofluores-
cence (Figure 1A).
To ensure long-term, reproducible, and defined si-
lencing effects, we generated Jurkat cells with stable
TCERG1 mRNA interference. Jurkat cell lines were
constructed by transfection of pGeneClip-shTCERG1
vectors. Jurkat-shTCERG1-(3-4) and Jurkat-shTCERG1-
(1-3-4) cell lines were generated by co-transfection with
pGeneClip-shTCERG1-3 and pGeneClip-shTCERG1-4
and/or pGeneClip-shTCERG1-1 vectors. The control
Jurkat-shTCERG1-C1 cell line was generated by trans-
fection with the pGeneClip-shTCERG1-1 vector. All of
the cell lines were tested for shRNA-mediated TCERG1
depletion by semiquantitative RT-PCR assay. Jurkat-
shTCERG1-(3-4) and Jurkat-shTCERG1-(1-3-4) cell lines
showed approximately 70% and 80% TCERG1 depletion,
respectively (Figure 1B). In agreement with our previous
data, we observed significantly reduced basal and Tat-
activated transcription from the HIV-1 LTR upon
TCERG1 knockdown in these Jurkat cells (Figure 1B).
We noted that the inhibition of transcription was
reduced in the presence of Tat in both cell systems
(compare right and left panels in Figure 1). This result
might indicate that TCERG1 acts on basal transcription
rather that on Tat-mediated trans-activation. Immuno-
fluorescence analysis indicated that TCERG1 has no effect
on the spatial localization of Tat (Figure 1B). Together,
these findings indicate that TCERG1 depletion affects
basal and Tat-mediated transcriptional activation of
the HIV-1 LTR in lymphoid cells. We conclude that
Figure 1 (See legend on next page.)
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Figure 1 TCERG1 depletion decreases basal and Tat-activated transcription from the HIV-1 LTR. A. PBLs were co-transfected with a
luciferase expression vector under the control of the HIV-1 LTR promoter (LTR-LUC) along with pGeneClip-shTCERG1-C1 or pGeneClip-shTCERG1-3
and pGeneClip-shTCERG1-4, and the latter pair together with pGeneClip-shTCERG1-1. The luciferase activity was quantified 72 hours after transfection
as relative light units (RLUs) using the control cells as the basal signal. Data from three independent experiments are represented in the histogram
(means ± SEM). Statistical analysis was performed and p-values are shown (**, p < 0.01; ***, p < 0.001). TCERG1 interference was determined by
immunoblotting. Appropriate expression and nuclear localization of Tat was evaluated by immunofluorescence using a specific antibody against Tat
and Dapi to stain the nucleus (a representative cell is shown). B. Jurkat cells with stable interference of TCERG1 were co-transfected with a luciferase
expression vector under the control of the HIV-1 LTR promoter (LTR-LUC) along with CMV-Tat101 or pcDNA3 as negative control. The luciferase activity
was quantified 72 hours after transfection as relative light units (RLUs) using the control cells as the basal signal. The results of three different
experiments are represented in the histogram (means ± SEM). Statistical analysis was performed, and p-values are shown (**, p < 0.01; ***, p < 0.001).
TCERG1 interference was determined by immunoblotting. The effect of TCERG1 interference on the expression and nuclear localization of Tat was
analyzed by immunofluorescence in all Jurkat cell lines with stable interference of TCERG1.
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from the HIV-1 LTR.TCERG1 depletion impairs elongation of HIV-1 transcripts
To test whether TCERG1 affects HIV-1 transcriptional
elongation, we measured the amount of transcripts gen-
erated at proximal and distal regions of the HIV-1 gene.
We transfected the Jurkat cell lines with the pNL4-3-wt
viral clone and assessed the amount of viral transcripts
by qRT-PCR. We designed specific primers directed
against the R/U5-gag and env/nef regions (Figure 2A).
We found that both early and late elongation of viral
transcripts was inhibited by approximately 50% in the
Jurkat-shTCERG1 cell lines (Figure 2B, left panel). To
lend support to the observation that TCERG1 affects
elongation, we measured the pre-mRNAs generated at
distal regions from a transiently transfected plasmid that
contains the complete pro-virus genome with a deletion
in the retrotranscriptase protein (pNL4-3ΔRT) under
conditions of TCERG1 knockdown in HEK293T cells.
We performed these experiments in HEK293T cells be-
cause we have previously observed that TCERG1 affects
the level of elongation-competent transcription complexes
in these cells [50]. The pNL4-3ΔRT DNA generates viral
particles in HEK293T cells that are able to enter target
cells, but due to the absence of reverse transcriptase, no
replication is detected. The cDNA was synthesized using
random hexamers followed by qPCR with primers ampli-
fying a region corresponding to the env gene (Figure 2A).
A plasmid expressing human growth hormone (pXGH5)
was also transfected and amplified by qPCR as a trans-
fection control (data not shown). The levels of RNA
were normalized to those of endogenous GAPDH. Simi-
larly with the data obtained in Jurkat cells (Figure 2B),
we observed a diminished accumulation of distal tran-
scripts by approximately 30-40% upon TCERG1 knock-
down (Figure 2C, left panel). The level of TCERG1
expression in silenced cells compared to that of CDK9
is also shown (Figure 2C, right panel). This result confirms
the previous data and further suggests that TCERG1 actsthrough an elongation mechanism in the regulation of
HIV-1 gene expression.
To directly test whether TCERG1 affects the rate of
RNAPII transcription, we used Padgett’s protocol. In this
procedure, 5,6-Dichlorobenzimidazole 1-β–D-ribofuranoside
(DRB), which reversibly blocks gene transcription
in vivo by inhibiting the P-TEFb-dependent Ser 2 phos-
phorylation of the CTD of RNAPII, is used in combi-
nation with qRT-PCR to analyze the transcription of
human genes [54]. To perform this protocol under opti-
mal conditions, we used T-Rex-HEK293 cell lines, which
ensure high transfection efficiency, in which expression of
control shRNA and shRNA targeting TCERG1 can be
induced by addition of tetracycline. The analysis of cell
lysates from induced cells showed that the cells that
contain shRNAs targeting TCERG1 express significantly
lower TCERG1 protein levels compared to the control
shRNAs (Figure 2D, right panel). Control and TCERG1-
knockdown cells were transfected with pNL4-3ΔRT and
pXGH5. The cells were treated with DRB, and samples
were collected at different time points after DRB removal.
Quantitative RT-PCR was performed using the primers in-
dicated above to amplify a region corresponding to the env
gene (Figure 2A). The DRB-treated control cells were
able to recover transcription within 20 to 80 min after
DRB removal, which is consistent with a transcriptional
lag due to the genomic distance from the start site of
transcription [54]. In contrast, transcriptional recovery
in TCERG1-knockdown cells was significantly slower
(Figure 2D, left panel). These results demonstrate a role
for TCERG1 in the RNAPII transcription of HIV-1 in vivo.
TCERG1 is present at the promoter and coding regions of
the HIV-1 gene
The above functional results and other published data
[51,53,55,56] indicate that TCERG1 associates with com-
ponents of the transcriptional machinery to regulate HIV-
1 transcriptional elongation. The point at which TCERG1
associates with the transcriptional complex during HIV-1
transcriptional activation remains an important question
in understanding TCERG1 function. To address this issue,
Figure 2 TCERG1 depletion impairs elongation of HIV-1 transcripts. A. Schematic representation of the HIV-1 genome. The black lines
indicate the position of each pair of primers used for qPCR experiments. B. Analysis by qPCR of the amount of nascent transcripts originated at
the proximal (LTR-gag) and distal (nef) regions of the pNL4-3-wt strain in Jurkat cells with stable interference of TCERG1 (left panel). The results of
three different experiments are represented in the histogram (means ± SEM; **, p < 0.01). TCERG1 mRNA interference was assessed by semi-qPCR
and immunoblotting using β-actin as the housekeeping gene and loading control, respectively (right panels). C. Quantitative analysis of the
amount of nascent transcripts originated at distal regions of the pNL4-3ΔRT provirus. HEK293T cells were transfected with siRNAs against EGFP
(siCTRL) or TCERG1 (siTCERG1) together with the pNL4-3ΔRT plasmid and pXGH5 as a transfection control. Total RNA was extracted and qRT-PCR
was performed using primers that amplify the env gene of the provirus (at positions 8010-8116). The graph shows the data from triplicates
of three independent experiments as values relative to those obtained from cells without siRNAs transfectiona (means ± SEM; **, p < 0.01).
D. Kinetics of RNAPII-dependent transcription elongation in the presence or absence of TCERG1. Control and TCERG1-knockdown T-Rex-HEK293
cells were transfected with pNL4-3ΔRT and pXGH5 as a transfection control and treated 48 h later with 100 μM DRB for 3 h. qRT-PCR was
performed using the primers that amplify the env gene of the provirus. The graph shows pre-mRNA levels at different times from the control and
TCERG1-depleted cells. The data shown are the averages from triplicates of three independent experiments (mean ± SEM). The analysis of
TCERG1 knockdown in T-Rex-HEK293 cells by Western blotting is shown on the right. CDK9 is used as loading control.
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First, to directly measure the transcribing RNAPII in
an in vitro transcription assay, we used an immobilized
template consisting of a biotinylated double G-less cassette
template driven by the HIV-1 LTR to isolate HIV-1 RNAPII
pre-initiation complexes (PICs) [35]. This template synthe-
sizes transcripts that contain two regions (cassettes) of
different sizes that lack guanosine residues; therefore,these G-less cassettes are resistant to digestion with
RNase T1. One G-less cassette is located proximal to the
promoter, enabling measurement of the numbers of tran-
scription complexes that reach nucleotide +183 (short),
while the second downstream G-less cassette measures
the number of transcripts beyond nucleotide +1960 (long)
(see Figure 3A). The biotinylated templates were incu-
bated with HeLa nuclear extract and subsequently isolated
Figure 3 Analysis of PICs assembled on the HIV-1 promoter in vitro. A. Experimental strategy for analyzing active PICs. Step 1: Cell-free
transcription reactions are performed using HeLa nuclear Extract (NE) and biotinylated templates carrying the HIV-1 LTR. Step 2: Transcription
complexes are purified by binding to streptavidin-coated magnetic beads. Step 3: Nascent RNA chains are labeled by incorporation of α-[32P]UTP.
A schematic representation of the HIV-1 double G-less cassette template used in the experiment is shown at the top of the panel. B. In vitro
transcription reactions were performed with the purified PICs. Lanes 1-3 represent three independent reactions performed using the HIV-1
template. Arrows indicate the migration of long and short transcripts. C. TCERG1 is a component of the HIV-1 PICs. PICs were formed on
constructs containing (lane 3) or not (lane 2) the HIV-1 promoter. PICs were purified with streptavidin-coated magnetic beads, and Western blot
analysis of the purified PICs was performed using the specific antibodies shown at the right side of the panel. The relative mobilities (in kDa) of
the molecular mass markers (M) are shown on the left side of the panel.
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in vitro transcription assays to test the activity of the
isolated transcription complexes. We observed clear
signals for the short and long transcripts (Figure 3B),
which indicated that the isolated complexes were com-
petent to transcribe the DNA sequences. We next ana-
lyzed the relative protein composition of the PICs
formed on the HIV-1 promoter sequences, especially
with respect to TCERG1. Figure 3C shows a represen-
tative immunoblot analysis of PICs using RNAPII-,
TCERG1-, Sp1-, TBP-, CDK9-, nucleolin-, and CDK2-
specific antibodies. As expected, RNAPII, Sp1, TBP, and
CDK9 were detected in the PICs formed on the HIV-1
promoter. Interestingly, TCERG1 was also found in the
PICs. We did not detect binding of nucleolin or CDK2
to the PICs. These results demonstrate the presence of
TCERG1 in the RNAPII complexes assembled onto the
HIV-1 promoter in vitro.
Next, we determined whether transiently transfected
TCERG1 is recruited to the HIV-1 LTR in vivo by
measuring the density of TCERG1 at specific regions of
the pNL4-3ΔRT gene using quantitative ChIP (qChIP)
analysis. We designed specific primers to detect TCERG1
recruitment at the 5′ LTR, gag, vif, env, and 3′ LTR
regions of the HIV-1 gene (Figure 4A). The qChIP ex-
periments revealed a specific association of TCERG1
at all these regions (Figure 4B). TCERG1 was notdetected using control IgG antibodies or control inter-
genic regions (Figure 4 and data not shown). These re-
sults indicate that TCERG1 specifically associates with
both, the promoter and downstream regions of the HIV-1
gene in vivo.TCERG1 depletion decreases phosphorylation of Ser2
within the RNAPII CTD
The above results demonstrate a specific association of
TCERG1 along the HIV-1 genome that resembles the
pattern of the RNAPII recruitment onto a gene unit.
In addition, transcriptional elongation is known to be
dependent on RNAPII CTD phosphorylation along the
transcribed gene [57,58]. Because TCERG1 has previ-
ously been shown to bind to the phosphorylated CTD
of RNAPII [52], we examined whether the observed de-
crease in the elongation rate of the enzyme (Figure 2D)
was due to changes in the CTD phosphorylation pattern.
To perform these experiments, we analyzed the phosphor-
ylation of the RNAPII CTD under conditions of TCERG1
knockdown or overexpression. We measured the density
of RNAPII at the 5′ LTR, gag, vif, env, and 3′ LTR regions
of a transiently transfected pNL4-3ΔRT provirus (see
Figure 4A) by qChIP analysis using specific antibodies
against total RNAPII (N20), Ser2, and Ser5 (Figure 5).
TCERG1 depletion resulted in a decreased accumulation
Figure 4 TCERG1 binds along the HIV-1 genome. A. Schematic representation of the HIV-1 genome. The black lines indicate the position of
each pair of primers used for qChIP experiments. B. TCERG1 distribution at different positions on the HIV-1 gene detected by ChIP followed by
qPCR in HEK293T cells transfected with the pNL4-3ΔRT provirus and a TCERG1 overexpression vector. IgG was used as a control in all ChIP
experiments. Data from four independent experiments are presented as percentages of the bound input.
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which was more pronounced at the distal positions of
the gene (Figure 5A). No differences were observed at
the promoter region upon TCERG1 knockdown. The
recruitment of RNAPII phosphorylated at Ser5 also
remained unaltered (Figure 5A). Conversely, TCERG1
overexpression resulted in an accumulation of total and
Ser2 polymerases at the same positions (Figure 5B).
These results indicate that TCERG1 is able to modify
CTD phosphorylation at Ser2, which may explain how
TCERG1 affects the dynamics of HIV-1 transcript
elongation.
TCERG1 did not change the overall amount of Ser2
phosphorylation or total RNAPII in the cell upon
TCERG1 depletion as assessed by immunoblotting
analysis (Additional file 1: Figure S1A). Compensatory
mechanisms to prevent loss of a protein as important
as the RNAPII may occur in the stable transfectant
cells. We detect a slight increase in the amount of
Ser2 phosphorylation and total RNAPII upon TCERG1
overexpression (Additional file 1: Figure S1B). The latter
result is in agreement with our ChIP data but caution
must be taken in interpreting these results because we
are measuring global Ser2 phosphorylation in the cell
and our ChIP experiments of Figure 5 are restricted to
the recruitment of RNAPII on the HIV-1 genome.TCERG1 is required for HIV-1 replication
Although previous experiments have implicated TCERG1
in HIV-1 LTR regulation using transient transfection
approaches, previous reports have not addressed the
functional implications of these findings on viral repli-
cation in vivo. Therefore, we conducted in vivo assays
to test whether TCERG1 can regulate HIV-1 replication.
PBLs isolated from healthy donors or Jurkat cells were
co-transfected with the HIV-1 infectious clone pNL4-3-
Renilla along with the pGeneClip-shTCERG1-C1 or
pGeneClip-shTCERG1-3 and pGeneClip-shTCERG1-4
and/or pGeneClip-shTCERG1-1 vectors. After 18 h, the
cells were collected and lysed, and Renilla luciferase
activity was measured. TCERG1 knockdown caused a
more than 2-fold reduction in HIV-1 replication in
PBLs and a more than 3-fold reduction in Jurkat cells
(Figure 6A). The TCERG1 interference was analyzed by
Western blot in both PBLs and Jurkat; β-actin was used
as the loading control (Figure 6B). The co-transfection
of a TCERG1 expression vector and the HIV-1 infectious
clone pNL4-3-Renilla produced the opposite effect on
HIV-1 replication with a more than a 2-fold increase in
the synthesis of Renilla in Jurkat cells (Figure 6C, left
panel). Overexpression of TCERG1 was assessed by
Western blot (Figure 6C, right panel). To lend additional
support to our data, Jurkat-shTCERG1 cell lines were
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Renilla. HIV-1 replication was reduced in both Jurkat-
shTCERG1-(3-4) and Jurkat-shTCERG1-(1-3-4) cell lines
(Figure 6D, left panel). Finally, to corroborate the notion
that the observed inhibition is a consequence of dimin-
ished viral replication, we measured the expression of
the p24 viral capsid protein. Measurement of HIV-1
p24 antigen levels is a highly specific assay for monitoring
HIV-1 replication and the progression of HIV-1 infection
[59] and correlates with the expression of Renilla [60].
We found that expression of p24 was inhibited by approxi-
mately 75% in TCERG1-silenced Jurkat cells compared
to control cells (Figure 6D, right panel). TCERG1 mRNA
and protein interference were analyzed by RT-PCR and
Western blot, respectively (Figure 6E). These data further
support the results of our previous experiments indicating
that TCERG1 is indeed required for HIV-1 replicationFigure 5 TCERG1 depletion decreases CTD Ser2 phosphorylation. A. T
polymerase II distribution at different positions of the HIV-1 genome was d
knockdown (KD) T-Rex-293 cell lines transfected with the pNL4-3ΔRT provi
using empty (control) and TCERG1 overexpression (OE) vectors. IgG was us
experiments are presented as percentages of the bound input (means ± SEin vivo. To lend additional support and specificity to our
data, we tested the effect of overexpressing TCERG1 on
HIV-1 replication in the Jurkat-shTCERG1 cell lines.
Transient overexpression of TCERG1 in TCERG1 knock-
down cells rescued HIV-1 replication (Figure 6F). Given
that Tat recruits the P-TEFb complex to the RNA TAR
element and activates transcription elongation through
phosphorylating the RNAPII CTD, we also sought to
assess the effect of CDK9 on TCERG1 depletion. To
this goal, we used expression plasmids for CDK9 and a
catalytically inactive CDK9 protein bearing a single
amino acid change (Asp-167 to Asn) in its active domain
(CDK9dn). Previous data have shown that CDK9dn is
functionally able to associate in vitro and in vivo with
Cyclin T [61]. And in Jurkat cells, overexpression of
Cdk9dn specifically inhibited Tat trans-activation and
HIV-1 replication [62] by preventing the endogenousotal polymerase (N20), phospho-Ser5 (Ser5) or phospho-Ser2 (Ser2)
etected by ChIP followed by qPCR in the control and TCERG1
rus. B. The same experiment described in panel A was performed
ed as a control in all ChIP experiments. Data from four independent
M).
Figure 6 TCERG1 is required for HIV-1 replication. A. PBLs and Jurkat cells were transiently transfected with the infectious clone
pNL4-3-Renilla along with pGeneClip-shTCERG1-C1 or pGeneClip-shTCERG1-3 and pGeneClip-shTCERG1-4, and the latter pair together with
pGeneClip-shTCERG1-1. Renilla was measured 72 hours after transfection, and RLUs are expressed relative to the control cells. B. Expression of
TCERG1 protein was assessed by Western blot in both PBLs and Jurkat. C. Jurkat cells were co-transfected with pNL4-3-Renilla and the pEFBOST7-
TCERG1 expression vector or empty pcDNA3 as the basal control. Overexpression of TCERG1 was assessed by Western blot. D. Jurkat cells with
stable TCERG1 mRNA interference (Jurkat shTCERG1-(3-4) and Jurkat shTCERG1-(1-3-4)) were transfected with pNL4-3-Renilla. Renilla activity was
measured in the infected cells (left panel), and p24 was measured in the culture supernatants (right panel); the data are expressed relative to the
control cells. E. The TCERG1 interference was analyzed in Jurkat shTCERG1-(3-4) and Jurkat shTCERG1-(1-3-4) by semiquantitative RT-PCR and
Western blot. F. The rescue of HIV-1 replication in Jurkat cells with stable TCERG1 mRNA interference (Jurkat shTCERG1-(3-4) and Jurkat
shTCERG1-(1-3-4)) transfected with pNL4-3_renilla vector was assessed by co-transfection with a TCERG1 expression vector (right panel), in
comparison with cells transfected with pcDNA3 as negative control (left panel). Renilla activity was measured and represented as RLUs; the data
are expressed relative to the control cells. The TCERG1 interference and overexpression was determined by Western blot. In all cases, the data
from three different experiments is represented in the histograms (mean ± SEM). Statistical analyses were performed and are shown as *, p < 0.05;
**, p < 0.01; ***, p < 0.001.
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CDK9dn fails to activate viral transcription indicating
that the kinase activity of CDK9 is essential for transcrip-
tion activation [35,63]. Our experiments with CDK9/
CDK9dn were designed to prove that our observations
were specific for HIV-1 and it could compensate (or not)
for a lack of TCERG1. Therefore, the experiments were
performed with a reporter LTR-HIV plasmid in order to
analyze the transcriptional effects of the proteins avoiding
the dominant negative effect of CDK9dn. Overexpressionof CDK9 did not rescue the LTR-dependent transcription
in the absence of endogenous TCERG1 (Additional file 2:
Figure S2).
Discussion
Our results help to explain the mechanism by which
TCERG1 functions in HIV-1 replication. We report that
TCERG1 is required for both basal and Tat-dependent
transcriptional activation in cells of the immune system,
which are the relevant targets in HIV-1 infection. Previous
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from transcriptionally-active HeLa nuclear extracts de-
creases Tat activation of RNAPII elongation efficiency
in vitro. However, TCERG1 does not bind directly to
Tat, and the presence of TCERG1 in the Tat affinity col-
umn was later suggested to be due to the association of
TCERG1 with other HIV-1 cofactors, such as P-TEFb and
Tat-SF1 [51]. Based on this possibility, it was conceivable
that removal of the TCERG1-associated Tat cofactors, not
removal of TCERG1 per se, provoked the decrease in Tat-
mediated activation of transcriptional elongation. Here, we
show that depletion of TCERG1 by gene silencing resulted
in decreased basal and Tat-activated transcription, thus
demonstrating a direct effect for TCERG1 in the regula-
tion of HIV-1 transcription. We show previously that
TCERG1 affects elongation in a promoter-specific fashion
[50,53] and a relatively small number of genes are af-
fected upon TCERG1 depletion by microarray analysis
[64]. Moreover, loss of tcer-1, the TCERG1 homologue
in C. elegans, has little or no effect on wild-type life-
span [65]. Thus TCERG1 is not likely to be a general
component of the transcriptional machinery, therefore,
the most probable interpretation of our experimental
data is that TCERG1 is affecting specifically to HIV-1
transcription. However, we cannot rule out the possibil-
ity of TCERG1 affecting cellular genes that are import-
ant for viral transcription.
The comparison of our results with those observed for
the other HIV-1 Tat cofactor, Tat-SF1 (which was also
identified by in vitro reconstituted transcription reactions
with immunodepleted extracts), is interesting. In recent
work, we show that depletion of Tat-SF1 by gene silencing
did not affect basal or Tat-dependent transcription from
an HIV-1 CAT reporter in HeLa and HEK293 cells [66].
These data contradict the results obtained by Caputi
and coworkers, which have recently reported that down-
regulation of Tat-SF1 by siRNAs induces a decrease in
transcription and Tat-mediated activation of an HIV-1
reporter minigene in HEK293 cells [67]. In this later
work, the effect of reduction of TCERG1 expression
was also analyzed. In contrast with our results, inhibition
of TCERG1 expression partially reduced Tat-mediated
trans-activation by paradoxically increasing the basal
transcription of the reporter construct [67]. Our experi-
ments with TCERG1 were predominantly performed in
Jurkat and PBLs, which are often used to examine tran-
scriptional regulation and HIV-1 infection in lymphocytes,
the natural targets of HIV-1. In agreement with the results
obtained in these cells, we also observed inhibition of
transcription from a proviral vector upon depletion of
TCERG1 in HEK293 cells (Figure 2C, Figure 2D, and
other data not shown). Therefore, caution must be taken
in interpreting the results obtained with Tat-SF1 and
TCERG1 knockdown since different results can beobtained in different contexts. Other elements in the
HIV-1 genome, the cell line used, and the chromatin
environment created by the different HIV-1 plasmids
could potentially contribute to the proper recruitment
and functionality of these Tat cofactors.
What is the mechanism for the decrease in HIV-1
transcription upon TCERG1 depletion? Our results pro-
vide a mechanism that is based on the RNAPII elongation
rate. First, we observed diminished accumulation of
transcripts upon TCERG1 knockdown (Figure 2B and
Figure 2C). Second, TCERG1 increased the rate of
RNAPII transcription (Figure 2D). Finally, we observed
that TCERG1 favors the phosphorylation of Ser2 of the
RNAPII CTD (Figure 5). Based on these results, we
propose that TCERG1 regulates HIV-1 transcription by
increasing the phosphorylation of Ser 2 on the heptad
repeats in the CTD, which facilitates the elongation of
RNAPII through the DNA template during gene activa-
tion. We have taken several approaches to assess the
recruitment of TCERG1 to the HIV-1 gene. Isolation
of PICs assembled onto a functional HIV-1 promoter
in vitro identified the presence of TCERG1 (Figure 3).
ChIP analysis confirmed the presence of TCERG1 at
the promoter region and distal elements (Figure 4). The
recruitment of TCERG1 correlates with the modulation
of Ser2 phosphorylation upon TCERG1 knockdown/
overexpression (Figure 5). These results are consistent
with a role for TCERG1 in the activation of HIV-1
transcriptional elongation that leads to the release of
RNAPII from promoter-proximal pausing. However we
cannot exclude the possibility that TCERG1 favors RNA-
PII processivity by acting at other locations within the
gene unit where polymerases could pause.
Very recently, a multi-component complex now called
the super elongation complex (SEC) has been isolated
through a sequential affinity-purification strategy to iden-
tify proteins associated with both Tat and P-TEFb [68].
In addition to Tat and P-TEFb, the SEC contains the
transcription factors ELL2, AFF4, ENL, and AF9. The
combined action of Tat, P-TEFb and the SEC results in
the synergistic activation of HIV-1 elongation by helping
to release RNAPII from promoter-proximal pausing and
promote the production of full-length viral transcripts
[68,69]. ELL2 is a well-characterized transcription elong-
ation factor and member of the ELL family of transcrip-
tion factors that stimulate elongation by increasing the
catalytic rate and suppressing transient pausing of RNAPII
[70,71]. Strikingly, we have identified ELL as a TCERG1-
interacting protein using a tandem affinity purification
(TAP) strategy (data not shown). Our data show that
overexpression of CDK9 did not rescue the HIV-1 LTR-
dependent transcription in the absence of endogenous
TCERG1 (Additional file 2: Figure S2). Based on these ob-
servations, it is an exciting possibility that TCERG1 affects
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cruitment and/or assembly of functional transcription
complexes.
One novel finding presented here is that TCERG1 is
required for HIV-1 replication (Figure 6). This require-
ment is likely due to the effect of TCERG1 on viral
transcription, although the precise mechanism by which
this factor functions remains unknown. Early data that
suggested a role for TCERG1 in HIV-1 replication found
that the levels of TCERG1 increased in Jurkat T cells
cultured with CXCL12 or the HIV-1 glycoprotein gp120
IIIB [72]. This expression was found to be dependent
on the presence of the HIV-1 co-receptor CXCR4 [72].
Recently, several studies using genome-wide RNAi experi-
ments have identified the so-called HIV dependency
factors (HDFs) [73-75]. TCERG1 was not identified in
any of these studies. However, the three siRNA screens
showed little overlap at the level of individual genes,
perhaps due to differences in the cell lines and HIV strains
used, the assay time post-infection or the procedures
used to measure infection. A recent work exploiting
the interactions identified in these RNAi screens in the
context of a human protein-protein interaction network
has predicted undiscovered HDFs that may play a role in
HIV-related disease progression in lymph nodes. Import-
antly, TCERG1 was one of the newly predicted HDFs in
this study [76].Conclusions
Although we have gained a considerable knowledge re-
garding the early events that occur at the promoter region
of genes to trigger the release of RNAPII for elongation,
several recent discoveries have suggested that events
subsequent to transcript initiation may also be necessary
for the production of full-length transcripts. Specifically,
the rate of elongation and pausing of RNAPII are generat-
ing considerable interest as critical regulators to ensure
precise and reliable control of gene expression. In this
scenario, factors that affect these processes could act as
checkpoint regulators to guarantee optimal RNAPII
activity. In this work, we describe the nuclear factor
TCERG1 as positive regulator of HIV-1 transcriptional
elongation by increasing the elongation rate of RNAPII
and phosphorylation of Ser 2 within the CTD. TCERG1
is therefore a candidate checkpoint factor that could
mediate functional links between elongation rates and
pausing.
The experiments reported here demonstrate an import-
ant role for TCERG1 in controlling HIV-1 transcriptional
elongation and replication. These studies suggest that
TCERG1 might be a plausible new target for anti-
retroviral therapy, thus opening interesting new ave-
nues for future investigation.Methods
Plasmids
The pNL4-3 wild-type (wt) plasmid, which contains the
complete HIV-1 genome and induces infectious pro-
geny after transfection, was kindly provided by Dr M.A.
Martin [77]. The pNL4-3-ΔRT plasmid was created by
deleting the reverse transcriptase gene of the pNL4-3
wt plasmid and was kindly provided by Dr Sánchez-
Palomino (Hospital Clínic, Barcelona) [78]. The pNL4-
3-Renilla plasmid was obtained by replacing the nef gene
in the HIV-1 proviral clone pNL4-3 with the Renilla lucif-
erase gene, as previously described [60]. The LTR-LUC
plasmid containing the luciferase (LUC) reporter gene
under the control of the HIV-1 LTR U3 + R region (LAI
strain) has previously been described [79]. The pCMV-
Tat101 plasmid has previously been described [80]. The
eukaryotic expression pEFBOST7-TCERG1 plasmid has
been previously described [50]. CDK9 and CDK9dn
expression plasmids were described previously [35]. The
GeneClip U1 Hairpin Cloning System kit (Promega
Biotech Iberica, Madrid, Spain), which contains the pGe-
neClip vector, was used to generate the following small
hairpin RNA (shRNA) plasmids: pGeneClip-shTCERG1-1,
pGeneClip-shTCERG1-3, and pGeneClip-shTCERG1-4)
containing three different small interference RNA (siRNA)
sequences directed against the mRNA encoding for
TCERG1. The sequences used to generate the pGeneClip-
shTCERG1-1 plasmid were shTCERG1-1 s (5′-TCTCGA
AGGAGTTGCACAAGATAAAGTTCTCTTATCTTGTG
CAACTCCTTCCT-3′) and shTCERG1-1 as (5′-CTGCAG
GAAGGAGTTGCACAAGATAAGAGAACTTTATCTTG
TGCAACTCCTTC-3′). The sequences used to generate the
pGeneClip-shTCERG1-3 plasmid were shTCERG1-3 s (5′-
TCTCGATCCTCGATGTATTAAGTAAGTTCTCTACTT
AATACATCGAGGATCCT-3′) and shTCERG1-3as (5′-CT
GCAGGATCCTCGATGTATTAAGTAGAGAACTTACT
TAATACATCGAGGATC-3′). The sequences used to gen-
erate the pGeneClip- shTCERG1-4 plasmid were shT




rambled sequences used to generate the pGeneClip-shT
CERG1-C1 plasmid were shTCERG1-C1s (3′-TCTCGG
ACTGGAAGTTCAAAGAAAAGTTCTCTTTCTTTGAA
CTTCCAGTCCCT-5′) and shTCERG1-C1as (3′-CTGC
AGGAGAGGCGTTTTAGAATATAGAGAACTTATATT
CTAAAACGCCTCTC-5′). Each pair of primers were
annealed and cloned in the linearized pGeneClip vector
according to the manufacturers’ instructions. The
pEGFP-C1 vector, which was used as control for moni-
toring transfection efficiency, was purchased from
Clontech (Mountain View, CA). Plasmids were purified
using the QIAGEN Plasmid Maxi Kit (Qiagen Iberia,
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ctions. The human growth hormone-expressing plasmid
pXGH5 was kindly provided by Dr Heiner Schaal
(University of Düsseldorf, Germany). The pEYFP-C1
vector (BD Biosciences, Clontech) was co-transfected as
a control for monitoring transfection efficiency and was
measured using a FACSCalibur flow cytometer (BD
Biosciences, Clontech).
Cells
The Jurkat cell line was cultured in RPMI 1640 medium
(BioWhittaker, Walkersville, MD) supplemented with 10%
fetal calf serum (PAN Biotech GmbH, Aidenbach,
Germany), 2 mM L-glutamine, 100 μg/ml streptomycin
and 100 U/ml penicillin (Lonza, Basel, Switzerland) at
37°C. PBMCs were isolated from the blood of at least
three different healthy donors by centrifugation through a
Ficoll-Hypaque gradient (Lymphocyte Separation Medium,
Lonza). The adherent monocytes were eliminated by keep-
ing the culture flask horizontal for 1 hour and then separ-
ating the non-adherent lymphocytes. These peripheral
blood lymphocytes (PBLs) were collected in supplemented
RPMI 1640 medium and maintained at 2 × 106 cells/ml
at 37°C.
Two Jurkat cell lines with stably interference for
TCERG1 were produced: Jurkat shTCERG1-(3-4), which
was co-transfected with both plasmids pGeneClip-shT
CERG1-3 and pGeneClip-shTCERG1-4 (1:1); and Jurkat
shTCERG1-(1-3-4), which was co-transfected with plas-
mids pGeneClip-shTCERG1-1, pGeneClip-shTCERG1-3,
and pGeneClip-shTCERG1-4 (1:1:1). The control cells
Jurkat shTCERG1-C1 were Jurkat stably transfected with
the control vector pGeneClip-shTCERG1-C1. All three
cell lines were grown in supplemented RPMI 1640
medium with 5 μg/ml puromycin (Invitrogen, Barcelona,
Spain) at 37°C.
HEK293T cells were grown in DMEM (Dulbecco’s
modified Eagle Medium, Gibco) with 10% fetal bovine
serum (Gibco) supplemented with penicillin/strepto-
mycin (100U and 0.1 mg/ml, respectively) and 4 mM L-
glutamine (Gibco).
The Flp-In T-Rex-293 cell line is a tetracycline-indu-
cible mammalian expression system (Invitrogen). Cells
were maintained in high glucose DMEM with 10% fetal
bovine serum supplemented with penicillin/streptomycin,
4 mM L-glutamine, and 15 μg/ml blasticidin (Invitrogen)
to select for cells expressing the Tet repressor plasmid.
To create inducible shRNA expressing cell lines, hairpin
sequences targeting either GFP (control) or TCERG1 were
cloned into pcDNA5/FRT/TO plasmid (Invitrogen) which
contains a CMV promoter with two tandem repeats of the
Tet operator. These constructs were transfected in the
Flp-In T-Rex-293cells along with pOG44 which expresses
the Flp recombinase. Stably transfected cells were selectedwith 200 μg/mL hygromycin and 15 μg/mL blasticidin.
5 μg/mL tetracycline (Sigma) was used for the induc-
tion of shRNA expression.
Reagents and antibodies
IL-2 was used at 300 U/ml (Chiron, Emeryville, CA).
Propidium Iiodide and 4′,6-diamidino-2-phenylindole
(Dapi) were obtained from Sigma-Aldrich. Specific anti-
bodies against TCERG1 have previously been described
[51]. Monoclonal antibody against HIV-1 Tat (aa 2-9) was
obtained from Advanced Biotechnologies Inc. (Columbia,
MD). Specific antibodies against the β-isoform of actin
were obtained from Sigma-Aldrich. Antibodies against
CDK9 (C-20, sc-484), and RNAPII (N20, sc-899), TBP
(N12, sc-204), CDK2 (M2, sc-163), and nucleolin (C23,
sc-13057) were obtained from Santa Cruz Biotechnol-
ogy. Anti-S5 and anti-S2 antibodies were obtained from
Abcam. Secondary antibodies conjugated to horseradish
peroxidase (HRP) were purchased from GE Healthcare
Spain (Madrid, Spain). Secondary antibodies conjugated to
Alexa-488 and Alexa-546 were purchased from Molecular
Probes (Eugene, OR).
Transfection assays
Stable transfection of Jurkat cells with pGeneClip-shT
CERG1-C1 or pGeneClip-shTCERG1-3 and pGeneClip-
shTCERG1-4 and/or pGeneClip-shTCERG1-1 vectors was
performed by electroporation with an Easyjet Plus Electro-
porator (Equibio, Middlesex, UK). In brief, 5 × 106 cells
were collected in 250 μl of RPMI without supplements
and mixed with 5 μg of DNA in an electroporation cuvette
with a 2 mm electrode gap (Equibio). The cells were trans-
fected by two pulses at 280 V, 150 μF, and 330 Ω. After
transfection, the cells were incubated in supplemented
RPMI for 18 h at 37°C. Puromycin was then added to the
culture medium at 0.5 μg/ml to select stable shRNA ex-
pressing cells. For transient transfections, approximately
5-10 × 106 cells were resuspended in 350 μl of RPMI
without supplements and mixed with 5-10 μg of DNA
in an electroporation cuvette with a 4 mm electrode
gap (Equibio). Jurkat cells were transfected by one
pulse at 280 V and 1500 μF and resting PBLs were
transfected by one pulse at 320 V and 1500 μF. After
transfection, the cells were incubated in supplemented
RPMI for 18 h at 37°C. The HIV-1 p24 antigen was
measured in cell culture supernatants by an enzyme-like
immunoassay (InnotestTM HIV Ag mAb; Innogenetics,
Barcelona, Spain). Luciferase and Renilla activities were
assayed using the Luciferase Assay System (Promega), and
transfection efficiency was monitored by flow cytometry
to measure the quantity of cells expressing EYFP. Relative
luciferase and Renilla units (RLUs) were measured in su-
pernatants with a Sirius luminometer (Berthold Detection
Systems, Oak Ridge, TN) after addition of the appropriate
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Galactosidase activity and total protein concentration
using the Bradford method [81].
For the RNA interference (RNAi) knockdown experi-
ments, HEK293T cells were grown in 60-mm plates
(Falcon) to 70-80% confluence and transfected using
Lipofectamine 2000 reagent (Invitrogen) according to
the manufacturers’ protocol with 60 nM of either one
of the following small interfering RNA (siRNA) du-
plexes: siEGFP, 5′-CUACAACAGCCACAACGE-3′, or
siTCERG1, 5′-GGAGUUGCACAAGAUAGUU-3′ [53].
Cells that did not receive siRNA were also used as a
control. After 48 h, the plasmids pNL4-3-ΔRT and
pXGH5 were co-transfected using Lipofectamine 2000.
Cells were harvested 24 h later. Under these conditions,
we consistently achieved at least ~80% knockdown of
TCERG1.RNA extraction and RT-PCR assays
Total RNA was isolated using the RNeasy Mini kit (Qiagen)
following manufacturer’s instructions. Specific primers
for amplifying a 431 bp fragment of the 3′-end of the
tcerg1 gene were as follows: TCERG1-s, 5′-AAGGCC
CGTTCAGAACAAACA-3′; and TCERG1-as, 5′-CGTCC
TGAAGTCAGCTTTGGCT-3′. Primers for amplifying
the human β-actin gene were as follows: β-actin-1 s,
5′-TCACCCACACTGTGCCCATCTA-3′, and β-actin-
1as, 5′-AGTTGAAGGTAGTTTCGTGGAT-3′, yielding a
fragment of 360 bp. The RT-PCR assay was performed in
a C1000 Thermal Cycler (Bio-Rad Laboratories, Madrid,
Spain) using the Access RT-PCR System (Promega).
Briefly, the reaction mix contained 5 μl of 5x buffer,
2 mM MgCl2, 0.1 mM dNTPs, 0.4 μM of each primer
pair, and 0.5 μl of each AMV Reverse Transcriptase and
Tfl DNA Polymerase in a final volume of 25 μl. A total
of 3 μg of RNA was added, and the thermal cycling
conditions were as follows: an initial cycle of 48°C for
45 min and 95°C for 10 min; 29 cycles of 95°C for
30 sec, 51°C for 1 min, 68°C for 45 sec; and a final
extension cycle of 68°C for 10 min. Amplified products
were analyzed by electrophoresis on a 3% SeaKem agar-
ose gel containing 5 μg/ml of ethidium bromide in 0.5x
Tris-acetate buffer. The specificity of the amplified
products was assessed by sequencing using an ABI
Prism 3700 DNA Analyzer (Applied Biosystems, Foster
City, CA).
For the analysis of the HIV genome elongation products
(Figure 2B), the Jurkat-shTGERC1-(3-4), Jurkat-shTGE
RC1-(1-3-4) and Jurkat-shTGERC1-C1 cells were trans-
fected with an infectious HIV-1 pNL4-3-wt clone and
cultured for 48 h. Total RNA was isolated using the
RNeasy Mini kit (Qiagen) following the manufacturer’s
instructions, and 5 μg of RNA was used to synthesizecDNA with the GoScript Reverse Transcription System
(Promega). Transcript elongation products were analyzed
using SYBR Green PCR Master Mix in an ABI-Applied
Biosystems 7500 Real Time Thermal Cycler (Applied
Biosystems). The reaction mixture contained 10 μl of
the PCR Master Mix and 0.4 μM of each primer pair in
a final volume of 20 μl. One microliter of cDNA was
added and amplified using the following conditions: an
initial 10 min denaturation step at 95°C and 36 cycles
consisting of 95°C for 15 sec, 60°C for 1 min, followed
by a continuous melting curve stage. The following
primers were used to amplify an early elongation prod-
uct, yielding a fragment of 303 bp: R/U5 (sense), 5′-
GGCTAACTAGGGAACCCACTGCTT-3′ (496-519) and
gag (antisense), 5′-CTCGCACCCATCTCTCTCCTTCT
A-3′ (777-799). To amplify a late elongation product, at
the beginning of the nef gene, primers P3 (sense), 5′-
TTGCTCAATGCCACAGCCAT-3′ (8654-8673) and P4
(antisense), 5′-TTTGACCACTTGCCACCCAT-3′ (8787-
8806) [82] were used and a fragment of 152 bp was
produced. Amplification of the gene encoding β-actin
was used as an internal control for data normalization
using the following primers: β-actin-2 s, 5′-AGGCC
CAGAGCAAGAGAGGCA-3′; β-actin-2as, 5′-CGCAG
CTCATTGTAGAAGGTGTGGT-3′, yielding a fragment
of 114 bp. All amplified products were analyzed by
electrophoresis on agarose gels and the specificity of
amplified products was assessed by sequencing. Densi-
tometry analysis was performed using Quantity One
software (Bio-Rad). Gel bands were quantified and
background noise was subtracted from the images. The
relative ratio of optical density units was calculated
relative to the gel band corresponding to the internal
control for each lane and each type of RNA sample.
For the experiment shown in Figure 2C, total RNA
was extracted from cells grown in 60-mm plates (Falcon)
as previously described [53]. Approximately 3 μg of
digested RNA was reverse transcribed using random
hexamers. The quantification of the transcripts derived
from the pNL4-3-ΔRT plasmid was performed by real-
time PCR using the PerfeCTa SYBR Green SuperMix for
iQ (Quanta Biosciences) and the iCycler thermal cycler
station (Bio-Rad) with the following primers: ENV-F, 5′-
TGGAAAACTCATTTGCACCA-3′ (8011-8027) and EN
V-R, 5′-TTCTCTGTCCCACTCCATCC-3′ (8097-8116).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as an internal control and was amplified using
the following primers: GAPDHfwd, 5′-ATGGGGGAA
GGTGAAGGTCG-3′ and GAPDHrev, 5′-GGGTCATT
GATGGCAACAATATC-3′. pXGH5 was used as a trans-
fection control and its products were amplified with
the primers hGH-fwd, 5′-CAACAGAAATCCAACC
TAGAGCTGCT-3′ and hGH-rev, 5′-TCTTCCAGCCT
CCCATCAGCGTTTGG-3′.
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assay
The purification of PICs and the in vitro transcription/
elongation assay were performed as previously described
[35].
Immunoblotting assays
Protein extracts were obtained as previously described [83].
Protein concentration was determined by the Bradford
method. Forty micrograms of protein extracts were
fractionated by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and transferred onto
Hybond-ECL nitrocellulose paper (GE Healthcare).
After blocking and incubation with primary and sec-
ondary antibodies, proteins were detected with Super-
Signal West Pico/Femto Chemiluminescent Substrate
(Pierce, Rockford, IL). Images were acquired using a Bio-
Rad Gel Doc 2000 (Bio-Rad). Densitometry was performed
as described above. For the experiment shown in Figure 4A,
we used protocols that have previously been described [53].
Immunofluorescence assays
For immunofluorescence assays, cells were immobilized
in PolyPrep slides (Sigma-Aldrich) for 15 minutes and
then fixed with 2% paraformaldehyde (PFA)-0.025% glu-
taraldehyde in PBS for 10 minutes at room temperature.
After washing twice with 0.1% glycine/PBS, cells were
permeabilized with 0.1% Triton X-100/PBS for 10 minutes.
Cells were then treated with 1 mg/ml NaBH4 for 10 mi-
nutes. Incubation for 1 hour at room temperature with
each primary and secondary antibodies and subsequent
washes were performed with PBS1x-2% BSA-0.05%
saponine buffer. Coverslips were immobilized with 70%
glycerol/PBS. Images were obtained with a Radiance
2100 confocal microscope (BioRad, Hercules, CA),
Leica TCS-SP confocal microscope (Leica Microsystems,
Wetzlar, Germany) or a Leica DMI 4000B Inverted Micro-
scope (Leica Microsystems).
Chromatin immunoprecipitation assay
Control and TCERG1 knockdown T-Rex-HEK293 cells
were seeded in 100-mm diameter plates at 70-80% con-
fluence and transfected with 6 μg of pNL4-3ΔRT plas-
mid. For overexpression experiments, T-Rex-HEK293
cells were additionally transfected with the pEFBOST7
empty vector or pEFBOST7-TCERG1 expression vector
using the calcium phosphate precipitation method.
After 48 h, the cells were fixed with 1% formaldehyde
and incubated at room temperature for 10 min. The
cross-link was arrested by adding glycine (0.125 M) for an
additional 5 min at room temperature. Subsequently,
the cells were pelleted, washed 3 times with phosphate-
buffered saline (PBS), and lysed in SDS lysis buffer
(1% SDS, 10 mM EDTA, 50 mM Tris-HCl [pH 8.1],protease inhibitor mixture [Complete; Roche], and 1 mM
phenylmethylsulfonyl fluoride [PMSF]) for 10 min on ice.
The lysates were sonicated 8 times for 15 s on ice and
centrifuged at maximum speed. The sheared chromatin
was diluted by the addition of 10 volumes of ChIP buffer
(0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM
Tris-HCl [pH 8.1], 167 mM NaCl, protease inhibitor mix-
ture, and 1 mM PMSF) and pre-cleared with a salmon
sperm DNA/protein A-agarose fast-flow slurry (Millipore)
for 2 h. The beads were removed by centrifugation. 5% of
the pre-cleared chromatin was removed to serve as the
pre-immunoprecipitation (pre-IP; input) control, and the
remaining pre-cleared chromatin was incubated overnight
with 5 μg of the specific antibodies or nonspecific rabbit
IgG. The chromatin-antibody complexes were collected
by incubation with salmon sperm DNA/protein-A agarose
(50% slurry) and centrifugation. Beads were washed in low
or high salt conditions using buffer (0.1% SDS, 1% Triton
X-100, 2 mM EDTA, 20 mM Tris-HCl [pH 8.1], and
150 mM NaCl) containing 20 mM and 500 mM NaCl, re-
spectively. The beads were then washed once with LiCl
buffer (0.25 M LiCl, 1% NP-40, 1% Na-deoxycholate,
1 mM EDTA, and 10 mM Tris-HCl [pH 8.0]) followed by
two washes with Tris-EDTA buffer. The antibody-chroma-
tin complexes were eluted from the beads by incubation
with elution buffer (0.1% SDS, 0.1 M NaHCO3). A final
concentration of 0.2 M NaCl was added to eluates, and
the samples were incubated at 65°C for 4-6 h. The samples
were treated with RNase A and proteinase K, and the
DNA was purified using phenol-chloroform extraction.
The pre-IP input sample was purified in a similar manner.
The DNA obtained was amplified by quantitative PCR
(qPCR) using PerfeCTa SYBR Green SuperMix for iQ
(Quanta Biosciences). The following primers were used:
5′-TAGTGTGTGCCCGTCTGTTG-3 (554-573) and 5′-
CGCTTTCAAGTCCCTGTTCG-3′ (643-662) for the 5′
LTR; 5′-AAAGGGCTGTTGGAAATGTG-3′ (2019-2038)
and 5′-GGCTCTGGTCTGCTCTGAAG-3′ (2131-2153)
for the gag gene; 5′-GTTTGGAAAGGACCAGCAAA-3′
(4929-4948) and 5′-CACAATCATCACCTGCCATC-3′
(5051-5070) for the vif gene; 5′-TGGAAAACTCATTTG
CACCA-3′ (8011-8027) and 5′-TTCTCTGTCCCACTC
CATCC-3′ (8097-8116) for the env gene; 5′-GGTGGGT
TTTCCAGTCACAC-3′ (8981-9000) and 5′-GGGAGT
GAATTAGCCCTTCC-3′ (9077-9096) for the 3′ LTR. Di-
lutions of the input were used to normalize the obtained
values. The results represent the average of four independ-
ent experiments.
RNAPII processivity assay
The rates of RNAPII transcription were measured as
previously described [53,54] with minor modifications.
Briefly, control and TCERG1 knockdown T-Rex-HEK293
cells were grown to approximately 70 to 80% confluence
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plasmids using Lipofectamine 2000 (Invitrogen) according
to the manufacturers’ protocol. The next day, the cells
were treated with 100 μM 5,6-Dichlorobenzimidazole
1-β–D-ribofuranoside (DRB) (Sigma) for 3 h. The cells
were washed with PBS to remove the DRB and incubated
in fresh medium for various periods of time. Total RNA
was then isolated using TRIzol reagent. The cDNA was
amplified by qPCR using the PerfeCTa SYBR Green
SuperMix for iQ (Quanta Biosciences) with primers
ENV-F and ENV-R. GAPDH was used as a reference
gene control and amplified with GAPDHfwd and
GAPDHrev. Amplification of pXGH5 with the primers
hGH-fwd and hGH-rev was used as transfection con-
trol. The CT was calculated as follows: (E pNL4-3-ΔRT)
ΔCT pNL4-3-ΔRT/(E GAPDH) ΔCT GAPDH, where E is the
PCR efficiency and ΔCT = CT for the control – CT for
DRB-treated cultures.Statistical analysis
Statistical analysis was performed using Graph Pad Prism
5.0 (Graph Pad Software Inc., San Diego, CA) with one-
way analysis of variance (ANOVA) followed by Bonferroni
post-test analysis to describe the significant differences
between groups. p-values (p) < 0.05 were considered
statistically significant in all comparisons and are repre-
sented as *, ** or *** for p < 0.05, p < 0.01 or p < 0.001,
respectively.Additional files
Additional file 1: Figure S1. Effect of silencing and overexpression of
TCERG1 on the expression and phosphorylation of RNAPII. Expression of
RNAPII and its phosphorylation on ser2 was analyzed by Western blot in
Jurkat cells with stable TCERG1 mRNA interference (Jurkat shTCERG1-(3-4)
and Jurkat shTCERG1-(1-3-4)), in comparison with control cells Jurkat
shTCERG1-C1 (A) and in Jurkat cells with transient overexpression of
TCERG1, in comparison with cells transfected with an empty pcDNA3
vector (B). β-actin was used as loading control.
Additional file 2: Figure S2. Overexpression of CDK9 did not rescue
the LTR-dependent transcription in the absence of TCERG1. Jurkat cells
with stable TCERG1 mRNA interference (Jurkat shTCERG1-(1-3-4)) were co-
transfected with LTR-LUC and a CDK9 expression vector (wild-type (wt)
or mutant (dn)) (right panel), in comparison with control cells Jurkat
shTCERG1-C1 (left panel). Luciferase activity was measured and
represented as RLUs; the data are expressed relative to the cells
transfected with pcDNA3. The CDK9 overexpression was determined by
Western blot. In all cases, the data from three different experiments is
represented in the histograms (mean ± SD). Statistical analyses were
performed and are shown as *, p < 0.05; **, p < 0.01; ***, p < 0.001.Abbreviations
TCERG1: Transcription elongation regulator factor 1; RNAPII: RNA polymerase II;
CTD: Carboxyl-terminal domain; LTR: Long terminal repeat; Ser: Serine;
PICs: Pre-initiation complexes.
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